Novartis AG
Company Snapshot
Founded: 1996
Entity Type: Public
Employees: 75,883
Region: U.S. and Europe
Revenue: $50,317.0 Millions
Revenue Year: 2024
Segment: Oncology
Headquarter: Basel, Switzerland
Corporate Address: Lichtstrasse 35 CH-4056 Basel, Switzerland Tel: +41-61-324-1111 Web: www.novartis.com
Company Overview
Novartis AG is a Swiss pharmaceutical company established in 1996 by the merger of Ciba-Geigy and Sandoz. The company actively engages in research and development and has a wide range of products, including innovative pharmaceuticals, generics, oncology drugs, biosimilars, and generics. Its products are available in 130 countries. Novartis AG was ranked fifth in sales among pharmaceutical manufacturers in 2023.
After the Sandoz business was spun off, Novartis began operations as a single global operating segment innovative medicines company on October 3, 2023. This company is now involved in developing, producing, distributing, commercializing, and selling innovative medicines.
Novartis AG In News
Company's Business Segments
- Cardiovascular, renal and metabolic : Entresto, Leqvio, and Other
- Immunology : Cosentyx, Xolai, Ilaris, and Other
- Neuroscience : Kesimpta, Zolgensma, Mayzent, Aimovig, and Other
- Oncology : Promacta/Revolade, Kisqali, Tafinlar + Mekinist, Tasigna, Jakavi, Pluvicto, Lutathera, Kymriah, Piqray/Vijoice, Scemblix, Votrient, Adakveo, Tabrecta, and other
- Established brands : Lucentis, Sandostatin, Gilenya, Exforge Group, Galvus Group, Diovan Group, Gleevec/Glivec, Afinitor/Votubia, Contract manufacturing, and Other
Applications/End User Industries
- Cardiovascular
- Immunology
- Neuroscience
- Oncology
- Metabolic
- Renal
BCC Research Beacon 